289 related articles for article (PubMed ID: 32447327)
21. Thyroid eye disease in Eastern Province of Saudi Arabia: clinical profile and correlation with vitamin D deficiency.
Alali M; Alkulaib NS; Alkhars A; Albadri K; Al Hassan S; Elewa M; Aldairi W; Alsaqer SK; Al-Abdulqader RA; Alhammad F
Orbit; 2024 Feb; 43(1):28-32. PubMed ID: 36855900
[TBL] [Abstract][Full Text] [Related]
22. Advances in steroid sparing medical management of active thyroid eye disease.
Liou VD; Yoon MK
Semin Ophthalmol; 2020 May; 35(4):216-223. PubMed ID: 32684074
[TBL] [Abstract][Full Text] [Related]
23. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
[No Abstract] [Full Text] [Related]
24. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial.
Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S;
Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670
[TBL] [Abstract][Full Text] [Related]
25. Clinical update: treatment of hyperthyroidism in Graves' ophthalmopathy.
Azzam I; Tordjman K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():193-7. PubMed ID: 20467362
[TBL] [Abstract][Full Text] [Related]
26. A Chinese survey of clinical practice on the management of thyroid eye disease.
Chen J; Li C; Teng W; Shan Z; Jin J; Wei Y; Sun J; Li Y; Zhou H
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642583
[TBL] [Abstract][Full Text] [Related]
27. Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy.
Strianese D; Rossi F
Eye (Lond); 2019 Feb; 33(2):191-199. PubMed ID: 30610229
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for Graves' ophthalmopathy.
Salvi M
Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
[TBL] [Abstract][Full Text] [Related]
29. Management plan and delivery of care in Graves' ophthalmopathy patients.
Yang M; Perros P
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):303-11. PubMed ID: 22632367
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapies for thyroid eye disease.
Kahaly GJ
Curr Opin Endocrinol Diabetes Obes; 2019 Oct; 26(5):250-255. PubMed ID: 31356255
[TBL] [Abstract][Full Text] [Related]
31. A Survey on the Management of Thyroid Eye Disease Among American and European Thyroid Association Members.
Brito JP; Nagy EV; Singh Ospina N; Zˇarković M; Dosiou C; Fichter N; Lucarelli MJ; Hegedüs L
Thyroid; 2022 Dec; 32(12):1535-1546. PubMed ID: 35946071
[No Abstract] [Full Text] [Related]
32. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy.
Campi I; Vannucchi G; Salvi M
Eur J Endocrinol; 2016 Sep; 175(3):R117-33. PubMed ID: 27032693
[TBL] [Abstract][Full Text] [Related]
33. Practical Guidelines Management of Graves Ophthalmopathy.
Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
[TBL] [Abstract][Full Text] [Related]
34. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
[TBL] [Abstract][Full Text] [Related]
35. [Biological treatment options for Graves' ophthalmopathy].
El Fassi D; Nielsen CH; Hegedüs L
Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
[TBL] [Abstract][Full Text] [Related]
36. Optimal management of Graves orbitopathy: a multidisciplinary approach.
Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
[TBL] [Abstract][Full Text] [Related]
37. Management of patients in a combined thyroid eye clinic in secondary care.
Benzimra JD; Quinn AG; Kersey T; McGrane D; Goss L; Vaidya B
Int Ophthalmol; 2014 Feb; 34(1):1-6. PubMed ID: 23549634
[TBL] [Abstract][Full Text] [Related]
38. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
Krassas GE
Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
[TBL] [Abstract][Full Text] [Related]
39. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
40. Understanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence.
Nivean PD; Madhivanan N; Kumaramanikavel G; Berendschot TTJM; Webers CAB; Paridaens D
Hormones (Athens); 2024 Mar; 23(1):25-34. PubMed ID: 37910311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
